{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T03:40:04Z","timestamp":1748835604064,"version":"3.41.0"},"reference-count":43,"publisher":"Informa UK Limited","issue":"5","funder":[{"name":"Simcere Zaiming Medical Technology Co., Ltd"},{"name":"State Key Laboratory of Neurology and Oncology Drug Development"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Pharmacoeconomics & Outcomes Research"],"published-print":{"date-parts":[[2025,5,28]]},"DOI":"10.1080\/14737167.2025.2478241","type":"journal-article","created":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T07:35:52Z","timestamp":1741592152000},"page":"751-760","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Cost-effectiveness analysis of trilaciclib for reducing the incidence of chemotherapy-induced myelosuppression among patients with extensive-stage small cell lung cancer in China"],"prefix":"10.1080","volume":"25","author":[{"given":"Nan","family":"Fang","sequence":"first","affiliation":[{"name":"Tianjin University","place":["Tianjin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuan","family":"Xia","sequence":"additional","affiliation":[{"name":"Tianjin University","place":["Tianjin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoning","family":"He","sequence":"additional","affiliation":[{"name":"Tianjin University","place":["Tianjin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2025,3,12]]},"reference":[{"key":"e_1_3_6_3_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834"},{"key":"e_1_3_6_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-00235-0"},{"key":"e_1_3_6_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/MAJ.0b013e3181bccef5"},{"key":"e_1_3_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2017.11.005"},{"key":"e_1_3_6_7_1","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol29120709"},{"key":"e_1_3_6_8_1","unstructured":"National comprehensive cancer network (NCCN) [internet]. Small cell lung cancer V2. 2025 [cited 2024 Sep 23]. Available from: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1462"},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200326100-00003"},{"key":"e_1_3_6_10_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2018.1558851"},{"key":"e_1_3_6_11_1","doi-asserted-by":"publisher","DOI":"10.2147\/IJCTM.S187569"},{"key":"e_1_3_6_12_1","doi-asserted-by":"publisher","DOI":"10.1177\/1758834014534515"},{"key":"e_1_3_6_13_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2021.2020570"},{"key":"e_1_3_6_14_1","first-page":"575","article-title":"\u80bf\u7624\u5316\u7597\u5bfc\u81f4\u7684\u4e2d\u6027\u7c92\u7ec6\u80de\u51cf\u5c11\u8bca\u6cbb\u4e2d\u56fd\u4e13\u5bb6\u5171\u8bc6 (2023\u7248) [Consensus on clinical diagnosis\uff0c treatment\uff0c and prevention of chemotherapy\u2043induced neutropenia in China (2023 edition)]","volume":"45","author":"China Anti\u2043Cancer Association Tumour Clinical Chemotherapy Professional Committee, China Anti\u2043Cancer Association Tumour Support Therapy Professional Committee","year":"2023","unstructured":"China Anti\u2043Cancer Association Tumour Clinical Chemotherapy Professional Committee, China Anti\u2043Cancer Association Tumour Support Therapy Professional Committee. \u80bf\u7624\u5316\u7597\u5bfc\u81f4\u7684\u4e2d\u6027\u7c92\u7ec6\u80de\u51cf\u5c11\u8bca\u6cbb\u4e2d\u56fd\u4e13\u5bb6\u5171\u8bc6 (2023\u7248) [Consensus on clinical diagnosis\uff0c treatment\uff0c and prevention of chemotherapy\u2043induced neutropenia in China (2023 edition)]. Chin J Oncol. 2023;45:575\u2013583. Chinese.","journal-title":"Chin J Oncol"},{"key":"e_1_3_6_15_1","first-page":"923","article-title":"\u80bf\u7624\u5316\u7597\u5bfc\u81f4\u7684\u4e2d\u6027\u7c92\u7ec6\u80de\u51cf\u5c11\u8bca\u6cbb\u4e13\u5bb6\u5171\u8bc6 (2019\u5e74\u7248) [Consensus on the clinical diagnosis, treatment, and prevention of chemotherapy- induced thrombocytopenia in China (2019 version)]","volume":"46","author":"The Society of Chemotherapy, China Anti-Cancer Association; Committee of Neoplastic Supportive-Care (CONS), China Anti-Cancer Association","year":"2019","unstructured":"The Society of Chemotherapy, China Anti-Cancer Association; Committee of Neoplastic Supportive-Care (CONS), China Anti-Cancer Association. \u80bf\u7624\u5316\u7597\u5bfc\u81f4\u7684\u4e2d\u6027\u7c92\u7ec6\u80de\u51cf\u5c11\u8bca\u6cbb\u4e13\u5bb6\u5171\u8bc6 (2019\u5e74\u7248) [Consensus on the clinical diagnosis, treatment, and prevention of chemotherapy- induced thrombocytopenia in China (2019 version)]. Chin J Clin Oncol. 2019;46:923\u2013929. Chinese.","journal-title":"Chin J Clin Oncol"},{"key":"e_1_3_6_16_1","first-page":"869","article-title":"\u4e2d\u56fd\u80bf\u7624\u5316\u7597\u76f8\u5173\u8d2b\u8840\u8bca\u6cbb\u4e13\u5bb6\u5171\u8bc6 (2019\u5e74\u7248) [A consensus on the clinical diagnosis, treatment, and prevention of cancer- and chemotherapy-related anemia in China (2019 edition)]","volume":"46","author":"The Society of Chemotherapy, Chinese Anti-Cancer Association; Committee of Neoplastic Supportive-Care (CONS), China Anti-Cancer Association","year":"2019","unstructured":"The Society of Chemotherapy, Chinese Anti-Cancer Association; Committee of Neoplastic Supportive-Care (CONS), China Anti-Cancer Association. \u4e2d\u56fd\u80bf\u7624\u5316\u7597\u76f8\u5173\u8d2b\u8840\u8bca\u6cbb\u4e13\u5bb6\u5171\u8bc6 (2019\u5e74\u7248) [A consensus on the clinical diagnosis, treatment, and prevention of cancer- and chemotherapy-related anemia in China (2019 edition)]. Chin J Clin Oncol. 2019;46:869\u2013875. Chinese.","journal-title":"Chin J Clin Oncol"},{"key":"e_1_3_6_17_1","unstructured":"National Comprehensive Cancer Network (NCCN) [Internet]. Clinical Practice Guidelines in Oncology. Hematopoietic growth factors version 1. 2025 [cited 2024 Sep 23]. Available from: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=3&id=1493"},{"key":"e_1_3_6_18_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aal3986"},{"key":"e_1_3_6_19_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-15-0775"},{"key":"e_1_3_6_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000847"},{"key":"e_1_3_6_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz278"},{"key":"e_1_3_6_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33453"},{"key":"e_1_3_6_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2023.107455"},{"key":"e_1_3_6_24_1","unstructured":"US Food and Drug Administration [Internet]. Trilaciclib product label; 2023 [cited 2024 Sep 19]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/214200s000lbl.pdf"},{"key":"#cr-split#-e_1_3_6_25_1.1","unstructured":"Chinese National Healthcare Security Administration [Internet]. [updated 2022 Jul 13"},{"key":"#cr-split#-e_1_3_6_25_1.2","unstructured":"cited 2024 Sep 19]. Available from: https:\/\/www.nmpa.gov.cn\/zwfw\/sdxx\/sdxxyp\/yppjfb\/20220713085333108.html"},{"key":"e_1_3_6_26_1","volume-title":"CSCO guidelines for diagnosis and treatment of small cell lung cancer (2024)","author":"Chinese Society of Clinical Oncology (CSCO)","year":"2024","unstructured":"Chinese Society of Clinical Oncology (CSCO). CSCO guidelines for diagnosis and treatment of small cell lung cancer (2024). 1st ed. Beijing: People\u2019s Medical Publishing House; 2024.","edition":"1"},{"key":"e_1_3_6_27_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2021.2014163"},{"key":"e_1_3_6_28_1","unstructured":"Tice JA Bloudek L McKenna A et al. Novel agents to prevent chemotherapy-induced neutropenia and other myelosuppressive Effects; revised evidence report. Boston: Institute for Clinical and Economic Review 2022. https:\/\/icer.org\/chemotherapy-induced-neutropenia-2022\/#timeline"},{"key":"e_1_3_6_29_1","unstructured":"Liu GG. China guidelines for pharmacoeconomic evaluations. China Market Press: Beijing; 2020."},{"key":"e_1_3_6_30_1","unstructured":"The people\u2019s bank of China [internet]. Announcement of the central parity of the RMB exchange rate. [cited 2024 Jul 15]. Available from: http:\/\/www.pbc.gov.cn\/zhengcehuobisi\/125207\/125217\/125925\/17105\/index2.html"},{"key":"e_1_3_6_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-012-0419-2"},{"key":"e_1_3_6_32_1","unstructured":"National Bureau of Statistics of China [Internet]. Statistical bulletin of national economic and social development of the people\u2019s Republic of China in 2023. [cited 2024 Feb 29]. Available from: https:\/\/www.stats.gov.cn\/sj\/zxfb\/202402\/t20240228_1947915.html"},{"key":"e_1_3_6_33_1","doi-asserted-by":"publisher","DOI":"10.1093\/acprof:oso\/9780190492939.001.0001"},{"key":"e_1_3_6_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41401-024-01297-6"},{"key":"e_1_3_6_35_1","unstructured":"YaoZh [Internet]. Inquiry of drug bid information. [cited 2024 Jun 26]. Available from: https:\/\/www.yaozh.com"},{"key":"e_1_3_6_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajco.12477"},{"key":"e_1_3_6_37_1","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200725030-00005"},{"key":"e_1_3_6_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2021.100060"},{"key":"e_1_3_6_39_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737167.2019.1650644"},{"key":"e_1_3_6_40_1","unstructured":"Chinese National Medical Products Administration [Internet]. List of accepted drug listing applications. [cited 2024 Sep 19]. Available from: https:\/\/www.cde.org.cn\/main\/xxgk\/listpage\/369ac7cfeb67c6000c33f85e6f374044"},{"key":"e_1_3_6_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2017.12.007"},{"key":"e_1_3_6_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-024-01352-4"},{"key":"e_1_3_6_43_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737167.2022.2091546"},{"key":"e_1_3_6_44_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-020-01611-w"}],"container-title":["Expert Review of Pharmacoeconomics & Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14737167.2025.2478241","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T03:04:10Z","timestamp":1748833450000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14737167.2025.2478241"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,12]]},"references-count":43,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5,28]]}},"alternative-id":["10.1080\/14737167.2025.2478241"],"URL":"https:\/\/doi.org\/10.1080\/14737167.2025.2478241","relation":{},"ISSN":["1473-7167","1744-8379"],"issn-type":[{"type":"print","value":"1473-7167"},{"type":"electronic","value":"1744-8379"}],"subject":[],"published":{"date-parts":[[2025,3,12]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierp20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierp20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-11-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}